Top Tweets for #WINTERFELL
Welcome to Winterfell Hall, where the North's most iconic moments came to life 👑
Book now to experience Winterfell Hall for yourself. Link in bio 🎬✨
#Winterfell
Moral of the story, When your wife says "leave the capital," maybe... leave the capital.. 😀🤓😄
#GameOfThrones #Winterfell #WifeAlwaysRight
$NWBO #DCVax ❄️ $MRK #Winterfell, the Long Night, and the Failed Trials
🏰 The Stronghold
Winterfell is the code name. WP50 is the building. Merck's three-floor facility at West Point, Pennsylvania, occupied early 2024, with sub-150°C cryogenic staging at the foundation, lyophilization paired with modular clean-room filling above, and no public program attribution. Sub-150°C exists for one reason: storing living cells. The architectural fingerprint specifically requires autologous cell therapy or equivalent living-cell modality. The lyophilization plus modular clean-room filling configuration is the signature of a lot factory, not a batch factory: many discrete patient-specific lots with chain-of-custody and release-testing as the rate-limiting bottlenecks. When Merck names its facilities (Wilmington for Keytruda biologics, Durham for vaccines, De Soto for Animal Health), it names them. WP50 carries no attribution. The selective silence is the anomaly. The stronghold is built before the war is declared.
The Long Night and the Army of the Dead
The metaphor extends through the entire combat ecology. In cancer immunology, the term cold tumor names a microenvironment with minimal T cell infiltration, suppressed dendritic cell function, and IL-6 to STAT3 to IRF8 silencing of IL-12 production. Cold tumors are unresponsive to checkpoint inhibitors because there is no inflammatory infiltrate to release. Cold tumors are the immunologically frozen territory beyond the Wall: glioblastoma, pancreatic adenocarcinoma, ovarian carcinoma, colorectal, the broader DCVax-Direct sixteen-tumor-type pipeline. The territory where the dead reign and the living do not return.
The army of the dead is the precise immunological match for the patient's exhausted T cell pool and silenced dendritic cell compartment. Cells present in the tumor microenvironment but not delivering the licensed Type-1 polarization signal needed for tumor clearance. They look alive by surface markers and population counts; they are not functioning. The molecular equivalent of the wight: the form of a soldier without the cellular instruction layer that makes the soldier engage.
The Night King is the silencing axis itself. The defining capacity of the Night King is the conversion of the living into the dead. The biological mechanism that converts a functioning immune cell into an exhausted one is the IL-6 to STAT3 to IRF8 silencing axis at the bone marrow dendritic cell progenitor layer. Chronic IL-6 from the tumor microenvironment phosphorylates STAT3, which silences IRF8, which eliminates IL-12 production, which exhausts the T cells that would otherwise engage the tumor. The Night King is the silencing axis. The army of the dead is the exhausted T cell pool the silencing axis produces.
Conventional weapons do not work against the army of the dead. Sword and arrow shatter on White Walker armor. Dragonglass and Valyrian steel are the only weapons that kill White Walkers. The αDC1 chemistry is the dragonglass of the metaphor. The mRNA cancer vaccine architecture is the conventional weapon.
The mRNA Architecture: Delivery to a Dead Instruction Layer
V940 was announced by Merck and Moderna in October 2022, with Merck exercising the development option following the Phase 2b mRNA-4157-P201 readout in melanoma at approximately two hundred fifty million dollars. V940 is engineered as mRNA-encoded patient-specific neoantigens in lipid nanoparticles, designed to deliver up to thirty-four computationally predicted neoantigens to the patient's endogenous dendritic cells. The lipid nanoparticle delivers the mRNA cargo to the DCs. The DCs take up the mRNA, translate the encoded peptides, process them through MHC class I and class II pathways, and present the neoantigens for T cell recognition. Pembrolizumab releases the checkpoint brake on the resulting T cell response.
The architecture is structurally identical to BNT122, which Roche and BioNTech announced in June 2016. BNT122 entered combination clinical development with the anti-PD-L1 antibody atezolizumab in the BNT122-01 melanoma Phase II. In October 2022, the BNT122-01 trial reported modest signal but not the durable response rate the program leadership had positioned for. The two leading checkpoint franchise owners (Merck with Keytruda, Roche with atezolizumab and Tecentriq) both executed the personalized mRNA neoantigen plus checkpoint combination as the architectural extension of their respective franchises. Both bets are structurally identical and addressed by the same architectural failure mode.
V940 presupposes the patient's endogenous dendritic cell compartment is Signal 3 competent. The V940 architecture delivers neoantigen substrate to the instruction layer it assumes exists. In immunologically cold tumors, the instruction layer is silenced. The IL-6 to STAT3 to IRF8 axis has eliminated IL-12 production at the bone marrow DC progenitor compartment. The patient's DC takes up V940 mRNA, presents the encoded neoantigens on MHC class I and II, delivers Signals 1 and 2 to the naive CD8 T cell, but cannot deliver Signal 3 above the Carreno IL-12p70 binary threshold (Journal of Clinical Investigation, 2013, approximately ten picograms per million cells per twenty-four hours). The T cell that receives Signals 1 and 2 without licensed Signal 3 exits the priming event toward exhaustion rather than execution-grade cytotoxicity.
V940 cannot fix what V940 presupposes. A second immunotherapy stacked on top of a first that has already failed cannot restore an instruction substrate neither modality carries. The mRNA delivers more antigen to a DC that cannot deliver the cytokine context that converts antigen into durable response. Steel swung against the army of the dead.
The #INTerpath Six-Trial Pattern
Merck and Moderna advanced V940 through the INTerpath designator across six disclosed trials. The trial portfolio is the empirical test of the platform's reach across the cold-to-hot tumor spectrum. INTerpath-001: Phase 3 in adjuvant resected high-risk melanoma, fully enrolled, readout approximately September 2026. INTerpath-002: Phase 3 in adjuvant resected non-small-cell lung cancer. INTerpath-004: Phase 2 in renal cell carcinoma. INTerpath-005: Phase 2 in urothelial carcinoma. INTerpath-007: Phase 2 in cutaneous squamous cell carcinoma, terminated October 2025 after approximately forty-six patients enrolled, without Phase 3 expansion. INTerpath-009: Phase 3 in NSCLC in the post-neoadjuvant setting. Six trials. Three Phase 3. Two Phase 2. One terminated.
The trial pattern maps onto the spectrum of endogenous DC competence across solid tumor indications. Melanoma has the most preserved endogenous DC compartment in the published cancer immunology literature. Tumor-infiltrating dendritic cell density is relatively high, baseline IL-12 production from those cells is relatively preserved, and melanoma's foundational role as the lead indication for checkpoint inhibitors traces directly to its relatively hot immunological status. INTerpath-001 advances to Phase 3 confirmation. The biology supports the bet in the easiest indication.
NSCLC has a more silenced endogenous DC compartment than melanoma but less silenced than the harder indications. INTerpath-002 and INTerpath-009 advance to Phase 3 confirmation across the resected and post-neoadjuvant settings respectively. Renal cell and urothelial carcinomas carry intermediate endogenous DC competence. Tumor-infiltrating DC populations vary substantially by patient and by molecular subtype. INTerpath-004 and INTerpath-005 remain at Phase 2 signal-finding, indicating Merck is still searching for the dose-effect signal that would justify Phase 3 advancement in these indications. The pattern is not random.
Cutaneous squamous cell carcinoma carries a heavily silenced endogenous DC compartment characteristic of HPV-driven and UV-driven head and neck malignancies. The cumulative chronic immune dysregulation in chronic actinic damage and HPV-driven malignancy is exactly the context where the IL-6 to STAT3 to IRF8 silencing axis has reached the most advanced state. INTerpath-007 terminated. The cold was complete; the conventional weapon failed.
The trial portfolio is the map of where the cold has not yet reached, where the cold has partially reached, and where the cold is total. The pattern is the empirical signature of a platform whose efficacy declines as the endogenous DC instruction layer becomes more silenced.
#INTerpath-007 as Prospective Falsification
INTerpath-007 terminated October 2025 after approximately forty-six patients enrolled. The termination followed KEYNOTE-630, the standalone pembrolizumab Phase 3 in the same cutaneous SCC indication, which had established that the underlying checkpoint inhibitor backbone in the V940 plus pembrolizumab combination had already failed in the indication before the combination was tested. INTerpath-007 is the first prospective falsification of the personalized mRNA neoantigen vaccine plus checkpoint inhibitor combination hypothesis in an indication where the Signal 3 deficit applies maximally.
Two layers of falsification are recorded. KEYNOTE-630 falsifies pembrolizumab monotherapy in cutaneous SCC: checkpoint release alone does not produce durable response when the underlying T cell priming layer is exhausted. INTerpath-007 falsifies V940 plus pembrolizumab combination in cutaneous SCC: adding mRNA-delivered neoantigen substrate to the failed checkpoint backbone does not produce durable response either, because the dendritic cell instruction layer V940 presupposes is silenced. Two empirical falsifications. Same indication. Same underlying instruction layer deficit. Two conventional weapons; both shattered against the same White Walker.
INTerpath-001 in September 2026 is the bidirectional event. Both outcomes carry the same implication for the αDC1 platform. If INTerpath-001 succeeds in melanoma (the easiest indication), the combination paradigm is validated where the endogenous compartment is most preserved, and an αDC1 instruction-installation architecture becomes the mechanistically required complement to extend the combination paradigm into the harder indications where the endogenous compartment is more silenced. If INTerpath-001 fails, the Signal 3 deficit has manifested at Phase 3 in Merck's flagship cancer vaccine program, and αDC1 becomes the required correction at the level of empirical Phase 3 evidence.
The six-trial pattern empirically demonstrates the V940 architecture cannot fix what V940 presupposes. The platform's reach is bounded by the endogenous DC competence of the indication being addressed. The cold tumor indications are structurally excluded from the V940 architecture's reach. mRNA does not work on cold tumors. The empirical record is in the trial portfolio.
The Dragonglass: Why αDC1 Works Where mRNA Fails
Pawel Kalinski first characterized dendritic cell exhaustion as the canonical failure mode of the legacy DC vaccine field in 1999. PGE2-containing maturation cocktails produced DCs with high CD83 expression, high migration capacity, and zero residual IL-12 production capacity. The legacy field's central failure was the engineering decision to use PGE2 in the maturation chemistry. The manufacturing process itself was producing wights rather than soldiers. Kalinski and Mailliard published the engineered solution in 2004. The αDC1 maturation chemistry replaces PGE2 with a five-component cocktail (IFN-α, IFN-γ, TNF-α, poly-I:C, IL-1β, applied for less than four hours), producing dendritic cells secreting IL-12p70 at approximately one hundred-fold increased output relative to legacy protocols. The IL-12 output is durable through the priming engagement at the lymph node compartment rather than burned out at manufacturing release.
The αDC1 platform is structurally distinct from mRNA cancer vaccines at the most consequential layer. mRNA delivers antigen substrate TO the patient's endogenous dendritic cells. αDC1 REPLACES the patient's endogenous dendritic cells with functional ones manufactured ex vivo. Where mRNA presupposes the instruction layer, αDC1 installs the instruction layer. Where mRNA arrives at a broken substrate in cold tumors, αDC1 delivers the substrate itself. The patient's T cell pool receives Signal 3 IL-12 above the Carreno binary threshold and exits priming activated rather than exhausted.
The αDC1 platform also reverses the silencing axis at the production layer. Downstream IFN-γ from the activated T cell pool reverses STAT3-mediated IRF8 silencing at the bone marrow hematopoietic stem and progenitor cell compartment. Subsequent dendritic cell generations are produced from the corrected bone marrow at restored IL-12 capacity. The Long Night ends because the source of the dead is corrected at the production layer. The patient's own bone marrow becomes the manufacturing facility for the corrected cascade across multiple cell generations.
The Kalinski Roswell Continuation
Kalinski continued the αDC1 chemistry development at Roswell Park through three architectural extensions. The Chemokine Modulatory regimen combines rintatolimod, IFN-α2b, and celecoxib to reshape the tumor microenvironment chemokine gradient toward CXCR3 and CCR5 effector T cell recruitment and away from regulatory T cell migration. The TGF-β resistant DC variant addresses the desmoplastic tumor microenvironment that defeats conventional αDC1 cells at the Signal 3 layer through TGF-β-mediated DC suppression; pancreatic adenocarcinoma, hepatocellular carcinoma, and the broader desmoplastic solid tumor category sit inside the TGF-β resistant variant's mechanistic reach. The next-generation peptide panel architecture covers HER2 and HER3 overexpressing malignancies, including HER2-positive and triple-negative breast cancer, gastric cancer, and the broader HER2-amplified solid tumor population. Three extensions. Three failure modes addressed beyond the base αDC1 chemistry. Three structural reaches into specific cold-tumor microenvironments where the base chemistry alone is insufficient.
The Three-Patent Perimeter
The patent record consolidates the full thirty-year Kalinski body of work into NWBio's corporate perimeter. US12059434B2 (Short-term Activated DC1s and Methods) is granted, jointly assigned to Health Research Inc. at Roswell Park and the University of Pittsburgh, and exclusively licensed to NWBio. It is the foundational manufacturing patent for any NWBio αDC1 product including DCVax-L, DCVax-Direct, and DCVax-T.
US20240299544A1 (Cancer Therapies Comprising Peptide Loaded CXCR3 and CCR5 Inducing Dendritic Cells and Chemokine Modulatory Agents) is pending at the USPTO, co-invented by Kalinski and Czerniecki, within the Roswell exclusive license closed June 12, 2024. The application claims the complete αDC1 maturation protocol combined with the HER2 and HER3 peptide panel, the Chemokine Modulatory regimen (rintatolimod plus IFN-α2b plus celecoxib), checkpoint inhibitor combinations including pembrolizumab, trastuzumab plus pertuzumab combinations, and adoptive T cell therapy through ex vivo αDC1 priming.
WO2025096694A1 covers the TGF-β resistant DC variant extending the platform mechanistic reach into pancreatic adenocarcinoma, hepatocellular carcinoma, and the broader desmoplastic solid tumor category where the TGF-β concentration at the tumor microenvironment exceeds the suppression threshold for standard αDC1 chemistry. The three patents together foreclose any company from sequencing dendritic cell vaccine plus checkpoint inhibitor across the global checkpoint franchise without licensing from NWBio. The dragonglass mine is consolidated under a single deed.
The Poly-ICLC Patent Bridge
Merck holds patent WO2022031314A2 covering scalable production of polyribonucleotides of controlled size. The synthesis chemistry applies directly to poly-ICLC (Hiltonol), the TLR3 agonist component disclosed by Dr. Marnix Bosch at the New York Academy of Sciences Frontiers in Cancer Immunotherapy conference on June 16, 2025 as part of the next-generation DCVax DC1 maturation supercharging cocktail. Poly-ICLC manufacturing requires lyophilization. Winterfell's second-floor lyophilization infrastructure is architecturally capable of producing the TLR3 adjuvant component of the next-generation αDC1 maturation chemistry under Merck's own manufacturing patent. The dragonglass forge inside the stronghold.
The manufacturing-IP plus infrastructure plus supercharging-component convergence is the manufacturing-bridge layer between Merck's adjuvant production capability and the NWBio αDC1 chemistry. Merck does not need to license poly-ICLC manufacturing from a third party. Merck owns the patent. The infrastructure to use the patent exists at the same site configured for living-cell modality storage and lot-factory filling.
The November 2025 Hire
On November 16, 2025, Merck posted a vaccinology postdoctoral fellow position at West Point, requisition R371970, filled by early 2026. The preferred qualifications enumerate the precise competency stack for evaluating the αDC1 plus supercharging adjuvant architecture preclinically: dendritic cell co-culture systems involving B and T cells, antigen presentation assays, BCR repertoire sequencing, ELISA, ELISPOT, high-parameter flow cytometry, cell sorting, in vitro restimulation assays, adjuvant evaluation focus. The position represented the first appearance of "dendritic cell" in a Merck West Point vaccinology posting per community-research review of historical postings at the site.
The hire is the Merck-side mirror of the NWBio operator-team pre-positioning pattern. A pharmaceutical company configuring a manufacturing facility for autologous cell therapy and hiring a dendritic cell vaccinology research fellow at the same location at approximately the same time is documenting the technology evaluation activity that necessarily precedes a partnership transaction. The steward is installed at the stronghold ahead of the announcement.
The #Keytruda 2028 LOE Clock
Keytruda faces composition-of-matter patent expiration approximately 2028 to 2030 across major global markets, with the US primary patent expiring 2028. Keytruda revenue exceeded thirty billion dollars in fiscal 2025, making it the largest single-product pharmaceutical franchise in history at peak. The replacement franchise architecture required to defend the checkpoint position into the post-2028 horizon must be operational by approximately 2027 to be commercially material at the LOE inflection. This is the long winter the Winterfell stronghold is prepared for.
#V940 plus Keytruda addresses the post-LOE franchise question in indications where the endogenous DC compartment is relatively competent. The growth indications Merck needs to enter to defend franchise scale are precisely the indications where V940 fails because the endogenous instruction layer is silenced: glioblastoma, pancreatic, colorectal, ovarian, the broader DCVax-Direct sixteen-tumor-type pipeline. The only published architecture addressing the silenced instruction layer is the integrated αDC1 platform that installs IL-12-competent dendritic cells from outside the patient's failed cascade. Merck cannot reach the cold tumor indications V940 alone cannot reach without licensing the DCVax architecture. The combination patent forecloses the alternative pathway. The 2028 LOE clock makes the partnership transaction timing structural rather than discretionary. Merck cannot defend the franchise into the long winter with steel alone.
Annalisa Jenkins as Integration-Node Operator
Annalisa Jenkins is the operator whose career signature is partnership architecture. She holds the M.B.B.S. and the Fellowship of the Royal College of Physicians, with Royal Navy medical officer service during the Gulf Conflict reaching surgeon lieutenant commander. She joined Bristol Myers Squibb and remained fifteen years, rising to Senior Vice President and Head of Global Medical Affairs, then served as Executive Vice President and Head of Global R&D at the biopharmaceutical division of Merck Serono with operational responsibility for more than sixty development programs. She served as President and CEO of Dimension Therapeutics, taking the company public on Nasdaq under DMTX and selling to Ultragenyx in November 2017 for approximately one hundred fifty-two million dollars cash at six dollars per share. Dimension was founded in 2014 from Harvard and Howard Hughes Medical Institute AAV gene therapy intellectual property; the arc is the closest career analog to what the NWBio platform requires: academic IP licensed into a corporate vehicle, translated through manufacturing development, exited through strategic acquisition.
She holds FDA Science Board membership at the institutional governance layer. She holds the Officer of the Order of the British Empire awarded in the King's 2026 New Year Honours announced December 29, 2025, conferred four months before the NWBio appointment. The UK life sciences governance portfolio includes The King's Fund, Genomics England, Protas, and the Institute of Directors launch with Freeman. She served four and one-half years at Ori Biotech before her April 1, 2026 elevation to Ori Chair. April 30, 2026: NWBio announces Jenkins as Strategic Adviser. Eight days separate the April 22, 2026 MHRA action on UK MIA 54923 commercial cell therapy manufacturing licence and the Jenkins appointment. Three dates within a thirty-day window. The credential stack is what executing a transatlantic pharmaceutical partnership operationalizing the αDC1 platform across MHRA, FDA, NHS, and US commercial deployment infrastructure requires.
The Convergence at the Stronghold
The convergence resolves at one location through five layers. Winterfell at the manufacturing layer. The Kalinski thirty-year body of work at the chemistry and intellectual property layer. The V940 INTerpath six-trial program at the empirical clinical evidence layer, with INTerpath-007 as the first prospective falsification and INTerpath-001 in September 2026 as the bidirectional event. The Keytruda 2028 loss of exclusivity at the partnership-transaction forcing-function layer. Annalisa Jenkins at the operator-execution layer.
The five layers converge because the biology routes them. The αDC1 chemistry is the only published architecture that installs the Signal 3 IL-12 cytokine context the V940 program demonstrated is missing across the spectrum of endogenous DC competence. The Pittsburgh and Roswell intellectual property perimeter forecloses the alternative pathway. The Keytruda 2028 loss of exclusivity establishes the timing. The Jenkins credential stack establishes the operator. The Winterfell stronghold establishes the manufacturing capability.
Winter is coming for the existing checkpoint franchise architecture. The army of the dead is at the gates: glioblastoma, pancreatic, ovarian, colorectal, the broader cold tumor portfolio that the silencing axis has converted from territory the patient's immune system should defend into territory the army of the dead now occupies. Conventional steel has failed in the coldest indications; INTerpath-007 is the empirical record. #KEYNOTE-630 is the empirical record one layer beneath. Two falsifications. Same indication. Same silenced instruction layer. The mRNA cancer vaccine plus checkpoint inhibitor combination architecture is bounded above by the endogenous DC competence of the indication being addressed, and the bound has now been documented at the cold end of the spectrum.
#Winterfell is the stronghold prepared at the manufacturing layer. Dragonglass is the αDC1 chemistry the stronghold will produce. The Night King is the IL-6 to STAT3 to IRF8 silencing axis. The αDC1 platform reverses the silencing at the production layer and ends the Long Night for the patient's bone marrow. The trigger event is the MHRA MAA decision. The biology decides.
https://t.co/eu0iz33h0P
Fire & Blood: Journey to The Unburnt
33 A.C. The Conquerors final progress
His Grace takes his final progress across The North to Winterfell
#ASOIAF #FireandBlood
🎨 by @nautieval
#AegonTargaryen #Winterfell
Happy April Fools' Day! 🃏
We tried to trick you with two truths and a lie... but did you spot it?
(Spoiler: We're not very good liars when it comes to Game of Thrones facts!)
🎟️ Link in bio to book your visit
#GameOfThrones #Winterfell #AprilFools #TriviaTime #ThingsToDoNI
Christian Pastor: Women should dress modestly.
Random Nigerian woman: Sharia is coming
#Winterfell
#Castleward today #northernireland #photography #photo #nationaltrust #history #gameofthrones #location historic 1700s house. Gardens amd featuring #winterfell from tvs Game of Thrones. Pics by philip john
Merck plans to split its main pharmaceutical unit in two as it prepares for the approaching patent expiry of its best-selling drug, according to the Wall Street Journal https://t.co/WB6CnJUlc6
The analysis logically connects public data on Merck's multi-billion investments in vaccine infrastructure (e.g., West Point expansions, NW2 BCR facility), a job posting mentioning dendritic cells, and NWBO's 2025 10-Q on U.S. GMP site selection. It's a plausible hypothesis for a partnership, but remains speculative without official confirmation.
"She had last seen snow the day she'd left Winterfell. That was a lighter fall than this, she remembered. "
commission art by @ Claudiaaa叶蓟 on 小红书, and the costume design is original by me
#sansa #asoiaf #housestark #winterfell
A Night In Winterfell | Whiskeyscapes | Ambient Medieval & Castle ASMR | Nostalgia and Dignity #whiskeyscapes #gameofthrones #winterfell #stark #medieval #kingdom #keep #castle #asmr #asmrcommunity #ambient #ambientvideo #ambientsound https://t.co/mwDPQ8a27G
It’s a proud moment for us, try and share your feedback on https://t.co/tyozNv7hFg.
#winterfell #ai #solana
getting recognized by the GOATs @kirat_tw and @shek_dev themselves is an honour to us,
holding the bar up from now on, moving towards the next level...
caught the part here:
https://t.co/0DaRV2qHj3
after that give @winterfell_dev a try,
https://t.co/wpw2EF5IoZ
A beautiful snowy scene this morning as I opened my curtains ❄️🥶😊❤️❤️ #Claudy #TheSperrins #Winterfell
Es ist so #warm im #Dezember, dass ich meinem Hund gesagt habe, dass er sich ganz umsonst sein #Winterfell angelegt hat!
Gut, dass es keinen #Klimawandel gibt! *sarcasm off*
Building a project is one thing and launching it into the wild is a whole different sport.
Once real users jump in, edge cases start showing up everywhere.
And no, you can’t just toss errors into the server abyss and call your backend “secure.”
#winterfell #ai
Last Seen Hashtags on Sotwe
Hermosa
Seen from Mexico
purespice
Seen from United States
codegold
Seen from United States
momson video----------------,,,,,,,,,,,,,,,
Seen from United States
종아리맞는
Seen from Korea
吃奶
Seen from Germany
ormanlıkalan
Seen from Turkey
patlicanoturtma
Seen from United States
momson(******) #omegle(**********************************************************) filter:videos
Seen from United States
Darkzadie
Seen from United States
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
241M followers
Barack Obama
@barackobama
119.2M followers
Cristiano Ronaldo
@cristiano
112M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
98M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
91.2M followers
KATY PERRY
@katyperry
88.5M followers
Taylor Swift
@taylorswift13
82.3M followers
Lady Gaga
@ladygaga
73.9M followers
Virat Kohli
@imvkohli
71.2M followers
Kim Kardashian
@kimkardashian
70.2M followers
YouTube
@youtube
68.7M followers
Bill Gates
@billgates
64.3M followers
Neymar Jr
@neymarjr
64M followers
The Ellen Show
@theellenshow
62.4M followers
CNN
@cnn
61.8M followers
Selena Gomez
@selenagomez
61.5M followers
X
@x
60.8M followers